Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Ensysce Biosciences, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 9 | 11 | +2 |
| Shares | 353.2K | 179.2K | −174.0K (−49.3%) |
| Value | $903.4K | $398.8K | −$504.6K (−55.9%) |
New holders (4)
Institutions that held Ensysce Biosciences, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 10,161 | $22.7K | 0.00% |
| SBI Securities Co., Ltd. | 2,336 | $5.21K | 0.00% |
| Morgan Stanley | 378 | $843 | 0.00% |
| Raymond James Financial Inc | 94 | $210 | 0.00% |
Sold out (2)
Institutions that held Ensysce Biosciences, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Murchinson Ltd. | 140,000 | $358.4K |
| Sabby Management, LLC | 46,954 | $120.2K |